BofA Raises its Price Target on American Healthcare REIT (AHR)
On May 22, 2026, BofA raised its price target for American Healthcare REIT (AHR) to $67 from $63 and kept a Buy rating, saying it updated REIT models. AHR also announced a May 20 underwritten offering of 14M shares priced at $50.40. In Q1, normalized FFO was 50c (vs 47c consensus) and revenue was $650.77M (below $687.04M).
How this was made
The 30-second read
Why it matters
The combination of (a) sell-side optimism (higher PT, Buy), (b) operational momentum (Q1 normalized FFO beat, double-digit same-store NOI growth), and (c) financing overhang (secondary priced below prior close) sets up a two-sided tape: supportive fundamentals but dilution/financing headlines can drive swings.
Market read
Near-term trading is likely dominated by how investors weigh the analyst PT increase and guidance raise versus dilution risk from the priced secondary offering.
What to watch
Watch whether the offering proceeds fund accretive acquisitions/development and whether same-store NOI growth and NFFO per share guidance sustain beyond the cited quarter strength.
Background
AHR is a diversified clinical healthcare REIT; the article links a recent Q1 beat and guidance raise with a new equity offering and a BofA valuation update.
Ticker impact
BofA raised AHR’s price target to $67 from $63 and reiterated Buy after updating REIT valuation models.
Bias toward modest upside or stabilization after the downgrade/dilution fears fade, with volatility around offering execution and any follow-through in FFO/NFFO guidance.
The article cites (1) BofA target increase and Buy rating, (2) Q1 normalized FFO ahead of consensus and raised full-year growth guidance, and (3) a 14M-share secondary priced below the prior close, which can pressure the stock despite capital-formation rationale.
Market effects
Model updates and target revisions across REITs suggest valuation sensitivity to assumptions; could influence sentiment for healthcare REIT peers.
Limited: AHR’s portfolio is US/UK/Isle of Man, but the catalyst is analyst modeling and capital markets activity.
Low: the news is primarily US sell-side and company-specific financing/earnings.
Counterpoint
The below-close secondary offering priced at $50.40 can signal near-term dilution and may cap upside even with a raised analyst target.
Key entities
- companyAmerican Healthcare REIT, Inc.
Subject of the article; BofA raised its price target, and the company recently announced a 14M-share secondary offering and reported Q1 results with guidance updates.
- analyst_firmBofA Securities
Raised AHR’s price target to $67 from $63 and maintained Buy after reviewing REIT valuation models.
